# Corcept Therapeutics Incorporated (CORT) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $111.62, market value $12.1 billion.

## Valuation
- **P/E (trailing): 248.0×** (5-yr avg 32.7×, 3-yr avg 39.3×). Corcept Therapeutics Incorporated trades at 248.0× trailing earnings, well above its own five-year average of 32.7×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 25.4×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 14.5×**. Each dollar of revenue is priced at 14.5×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 17.1×**. The shares trade at 17.1× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: 0.9%** (5-yr avg 4.4%). Free cash flow equals 0.9% of the market value, below its five-year average of 4.4%, so the shares are pricier on cash than usual.
- **Earnings yield: 0.4%**. The inverse of the P/E: 0.4% of the price is earned each year.

## Profitability
- **Operating margin: 0.8%**. 0.8% of revenue is left after running the business, which leaves little cushion in a downturn.
- **Net margin: 13.1%**. 13.1% of each dollar of sales reaches the bottom line.
- **Return on equity: 15.4%**. 15.4% on shareholders' equity is solid.
- **Return on invested capital: 1.0%**. Return on all capital, debt included, is 1.0%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: 6.6%**. Each dollar of assets produces 6.6% of profit.

## Growth
- **Revenue growth (1 yr): 12.8%** (3-yr 23.7%/yr, 5-yr 16.6%/yr). Revenue grew 12.8% over the last year, against 16.6% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -33.3%** (3-yr -2.0%/yr, 5-yr -0.7%/yr). Earnings per share fell 33.3%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): 5.7%/yr**. Free cash flow has compounded at 5.7% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Corcept Therapeutics Incorporated holds more cash than debt.
- **Current ratio: 2.92** (quick 2.92). Current assets cover the next year's liabilities 2.92 times.
- **Altman Z-score: 40.96**. A Z-score of 40.96 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Corcept Therapeutics Incorporated does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (5 analysts). 5 analysts cover Corcept Therapeutics Incorporated; the consensus is buy, with an average price target of $141.00 (+26% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 60.9%** (YTD 220.7%, 3-mo 53.7%). The shares are up 60.9% over twelve months including dividends.
- **From 52-week high: -11.7%** (289.5% above the low). Trading 12% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 50**. An RSI of 50 is neutral.
- **Beta (1 yr): 1.81** (volatility 82%). Beta of 1.81 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CORT · Page: https://foliofundamentals.com/stocks/cort

Not investment advice.